Biogen Idec 3Q11
 

3Q Revenues: $1.3 billion (+11%)
 

3Q Earnings: $352 million (+38%)
 

YTD Revenues: $3.7 billion (+6%) 
 

YTD Earnings: $966.5 million (earnings were $626.8 million 3Q10)
 

Comments: Global in-market sales of Tysabri were $393 million in the quarter (+28%). Avonex sales increased 6% to $682 million. Rituxan revenues from the company’s joint business arrangement with Genentech were $266 million (+3%). Royalties were $52 million in the quarter, up 43%.